Sooma
Private Company
Funding information not available
Overview
Sooma Medical is a commercial-stage medical device company pioneering accessible transcranial direct current stimulation (tDCS) therapy for depression and chronic pain. Its core innovation combines a portable stimulation device with a remote protocol management platform, enabling scalable treatment delivery in clinics or at home. With over 30,000 patients treated across 35+ countries and the first EU MDR approval for a tDCS system, Sooma has established early market leadership. The company is now advancing a U.S. FDA clinical trial to expand into the critical American market.
Technology Platform
Portable transcranial direct current stimulation (tDCS) medical device integrated with a remote cloud-based protocol management and monitoring software platform for the treatment of neurological and psychiatric conditions.
Opportunities
Risk Factors
Competitive Landscape
Sooma competes in the neuromodulation space, primarily against more established Transcranial Magnetic Stimulation (TMS) systems for depression and various pharmacological treatments. Its key differentiators are its EU MDR approval, portability for home-use, and integrated remote management platform. It faces competition from other tDCS device makers, though it claims global prescription leadership.